Astellas Pharma Financials
| ALPMY Stock | USD 10.08 0.20 1.95% |
Astellas |
Understanding current and past Astellas Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Astellas Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Astellas Pharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Astellas Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Astellas Pharma. Check Astellas Pharma's Beneish M Score to see the likelihood of Astellas Pharma's management manipulating its earnings.
Astellas Pharma Stock Summary
Astellas Pharma competes with Sanofi ADR, Bristol Myers, AstraZeneca PLC, Gilead Sciences, and Novartis. Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US04623U1025 |
| Business Address | 2-5-1, Nihonbashi-Honcho, Tokyo, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.astellas.com |
| Phone | 81 3 3244 3000 |
| Currency | USD - US Dollar |
Astellas Pharma Key Financial Ratios
Astellas Pharma's financial ratios allow both analysts and investors to convert raw data from Astellas Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Astellas Pharma over time and compare it to other companies across industries.| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Target Price | 15.38 | |||
| Beta | 0.51 | |||
| Z Score | 3.0 |
Astellas Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Astellas Pharma's current stock value. Our valuation model uses many indicators to compare Astellas Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Astellas Pharma competition to find correlations between indicators driving Astellas Pharma's intrinsic value. More Info.Astellas Pharma is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Astellas Pharma is roughly 1.38 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Astellas Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Astellas Pharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Astellas Pharma Systematic Risk
Astellas Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Astellas Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Astellas Pharma correlated with the market. If Beta is less than 0 Astellas Pharma generally moves in the opposite direction as compared to the market. If Astellas Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Astellas Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Astellas Pharma is generally in the same direction as the market. If Beta > 1 Astellas Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Astellas Pharma December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Astellas Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Astellas Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Astellas Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Astellas Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Astellas Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.24) | |||
| Maximum Drawdown | 10.71 | |||
| Value At Risk | (3.45) | |||
| Potential Upside | 2.27 |
Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.